Literature DB >> 4729926

Determinants of serum antipyrine half-lives in patients with liver disease.

R A Branch, C M Herbert, A E Read.   

Abstract

Antipyrine has been used as a model drug to investigate the effects of liver disease on drug metabolism in man. A prolongation in antipyrine half-life (T(1/2)) was found in patients with liver disease, patients with chronic liver disease showing a greater increase than those with acute, reversible pathology. The most marked prolongation in T(1/2) was found in association with hypoalbuminaemia and hypoprothrombinaemia, suggesting that the cause for these changes was defective protein synthesis of microsomal enzyme protein. This hypothesis was supported by demonstrating that enzyme-inducing agents, which are known to increase the amount of microsomal enzyme protein, reduced the antipyrine half-life.

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4729926      PMCID： PMC1412804          DOI： 10.1136/gut.14.7.569

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  14 in total

1.  Adaptive increases in drug-metabolizing enzymes induced by phenobarbital and other drugs.

Authors:  A H CONNEY; C DAVISON; R GASTEL; J J BURNS
Journal:  J Pharmacol Exp Ther       Date:  1960-09       Impact factor: 4.030

2.  Observations on the metabolic transformation and effects of phenylbutazone in subjects with hepatic disease.

Authors:  M WEINER; T CHENKIN; J J BURNS
Journal:  Am J Med Sci       Date:  1954-07       Impact factor: 2.378

3.  Influence of nitrazepam on oral anticoagulation with phenprocoumon.

Authors:  R Bieger; H de Jonge; E A Loeliger
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

4.  Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy.

Authors:  A J Levi; S Sherlock; D Walker
Journal:  Lancet       Date:  1968-06-15       Impact factor: 79.321

5.  Pharmacodynamics of carbenicillin in hepatic and renal failure.

Authors:  T A Hoffman; R Cestero; W E Bullock
Journal:  Ann Intern Med       Date:  1970-08       Impact factor: 25.391

6.  Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man.

Authors:  R E Stenson; R T Constantino; D C Harrison
Journal:  Circulation       Date:  1971-02       Impact factor: 29.690

7.  The effect of hepatic blood flow on the hepatic removal rate of oxyphenbutazone in the dog.

Authors:  T L Whitsett; P G Dayton; J L McNay
Journal:  J Pharmacol Exp Ther       Date:  1971-04       Impact factor: 4.030

8.  Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.

Authors:  E S Vesell; J G Page
Journal:  J Clin Invest       Date:  1969-12       Impact factor: 14.808

9.  Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease.

Authors:  G Acocella; L Bonollo; M Garimoldi; M Mainardi; L T Tenconi; F B Nicolis
Journal:  Gut       Date:  1972-01       Impact factor: 23.059

10.  Metabolism of amylobarbitone in patients with chronic liver disease.

Authors:  G E Mawer; N E Miller; L A Turnberg
Journal:  Br J Pharmacol       Date:  1972-03       Impact factor: 8.739
View more
  62 in total

Review 1.  Altered hepatic blood flow and drug disposition.

Authors:  A S Nies; D G Shand; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

2.  The effect of cirrhosis on the disposition and elimination of clindamycin.

Authors:  G R Avant; S Schenker; R H Alford
Journal:  Am J Dig Dis       Date:  1975-03

3.  Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction.

Authors:  G W Hepner; E S Vesell
Journal:  Am J Dig Dis       Date:  1975-01

4.  Disposition of antipyrine in patients with extensive metastatic liver disease.

Authors:  G M Robertz-Vaupel; K D Lindecken; T Edeki; C Funke; S Belwon; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Pharmacokinetics in the elderly.

Authors:  E J Triggs; R L Nation; A Long; J J Ashley
Journal:  Eur J Clin Pharmacol       Date:  1975       Impact factor: 2.953

6.  Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease.

Authors:  M Homeida; C J Roberts; M Halliwell; A E Read; R A Branch
Journal:  Gut       Date:  1979-07       Impact factor: 23.059

7.  Antipyrine disposition and liver size in the elderly.

Authors:  C G Swift; M Homeida; M Halliwell; C J Roberts
Journal:  Eur J Clin Pharmacol       Date:  1978-11-16       Impact factor: 2.953

8.  Tyramine kinetics and metabolism in cirrhosis.

Authors:  B A Faraj; J T Fulenwider; E B Rypins; B Nordlinger; G L Ivey; R D Jansen; F M Ali; V M Camp; M Kutner; F Schmidt; D Rudman
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

9.  Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

Authors:  D Fabre; F Bressolle; R Goméni; O Bouvet; A Dubois; C Raffanel; J C Gris; M Galtier
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

10.  Antipyrine metabolism in cancer patients.

Authors:  T Higuchi; T Nakamura; H Uchino
Journal:  Experientia       Date:  1980-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.